The anti–interleukin-5 antibody mepolizumab is useful for treating bronchial asthma and eosinophilic polyangiitis granulomatosa, and its efficacy in eosinophilic esophagitis has also been investigated. This evidence concerns the gene IL5 and eosinophilic esophagitis.